Recombinant Human IFNAR2 protein

中文名： 干扰素α/β受体2(IFNAR2)重组蛋白
别名： IFNAR2；IFNABR；Interferon alpha/beta receptor 2

货号: PA1000-4070

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>95%SDS-PAGE.
种属	Human
靶点	IFNAR2
Uniprot No	P48551
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	27-243aa
氨基酸序列	ISYDSPDYTDESCTFKISLRNFRSILSWELKNHSIVPTHYTLLYTIMSKP EDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLFSCSHNF WLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEG IVKKHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLK CTLLPPGQESESAESAKVDHHHHHH
预测分子量	26 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于IFNAR2重组蛋白的3篇参考文献的简要总结(注：文献信息为模拟示例，实际引用请核实原文)：

1. **"Structural basis of interferon receptor assembly and signaling"**

*作者：Garcia, K.C. et al.*

摘要：该研究通过X射线晶体学解析了IFNAR2重组蛋白与干扰素β结合的复合物结构，揭示了受体胞外域的构象变化及其在JAK-STAT信号通路启动中的关键作用。

2. **"Functional characterization of soluble IFNAR2 in antiviral responses"**

*作者：Uzé, G. & Pellegrini, S.*

摘要：文章探讨了可溶性重组IFNAR2蛋白在体外和动物模型中的抗病毒效应，证明其通过竞争性结合干扰素抑制病毒复制，为治疗慢性病毒感染提供了潜在策略。

3. **"IFNAR2 isoforms differentially regulate interferon signaling outcomes"**

*作者：de Weerd, N.A. et al.*

摘要：研究比较了两种IFNAR2重组蛋白亚型(长/短胞内域)在信号传导中的差异，发现短亚型通过负反馈机制减弱STAT磷酸化，影响干扰素抗增殖与免疫调节功能。

注：以上为基于领域知识的模拟文献，建议通过PubMed或Google Scholar以“IFNAR2 recombinant protein”为关键词检索最新论文获取真实参考文献。

背景信息

IFNAR2 (Interferon Alpha and Beta Receptor Subunit 2) is a critical component of the type I interferon (IFN) receptor complex, which mediates cellular responses to IFN-α and IFN-β—key cytokines involved in antiviral defense, immune regulation, and antitumor activity. As a transmembrane protein, IFNAR2 pairs with IFNAR1 to form a functional receptor that binds type I IFNs, triggering intracellular signaling via the JAK-STAT pathway. This signaling cascade activates genes encoding proteins with antiviral, antiproliferative, and immunomodulatory effects.

Recombinant IFNAR2 proteins are engineered to mimic the extracellular domain of the native receptor, often fused with tags (e.g., Fc or His tags) for purification and detection. These proteins are produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper glycosylation and structural fidelity. Researchers use recombinant IFNAR2 to study receptor-ligand interactions, screen for IFN agonists/antagonists, or develop therapeutic strategies targeting type I IFN pathways. For example, soluble IFNAR2 can act as a decoy receptor to modulate excessive IFN signaling in autoimmune diseases like lupus. Conversely, enhancing IFNAR2 stability or expression may improve IFN efficacy in cancer immunotherapy.

Additionally, recombinant IFNAR2 aids in elucidating mechanisms of viral immune evasion, as pathogens often disrupt IFN signaling by interfering with receptor function. Its applications extend to diagnostics, such as detecting autoantibodies against IFNAR2 in certain diseases. Ongoing research explores its therapeutic potential in chronic infections, inflammatory disorders, and as a component of engineered IFN variants with tailored pharmacokinetics. Overall, recombinant IFNAR2 serves as a versatile tool for both basic research and translational innovation in immunology and virology.